The researchers say that, to their knowledge, this is the first demonstration of programmable, site-specific integration of a large DNA payload into T cells in vivo.
With clinical data beginning to emerge, big pharma is signaling its belief that in vivo CAR generation is the next immunotherapy breakthrough.
Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s first commercial viral vector Contract Development and Manufacturing Organisation (CDMO), today announces that it has entered into a ...
CTNS-RD-04, an ex vivo gene therapy for cystinosis, showed reduced white-cell cystine levels and an acceptable safety profile ...
Next step in a broader collaboration to support VVMF build viral vector manufacturing capabilities Oxford, UK – 18 March 2026: OXB (LSE: OXB), a ...
As previously announced, OXB will report its preliminary results for the twelve months ended 31 December 2025 on 26 March ...
ReiThera, the Italian leading Contract Development and Manufacturing Organization (CDMO) specialized in the development and GMP manufacturing of viral vectors for gene therapies and vaccines, is ...
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its 2025 ...
Investigators at CHOP and UPenn found that lower cell counts could still be associated with poor outcomes if the cells were poorly differentiated.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results